Sign In
Buy RLAY
$15.30
-0.400 (-2.55%)
At Close: Jun 03, 2026
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
04:05pm, Thursday, 31'st Jul 2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
12:36pm, Friday, 25'th Jul 2025
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
04:05pm, Wednesday, 11'th Jun 2025
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
04:05pm, Thursday, 29'th May 2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edg
What Makes Relay Therapeutics (RLAY) a New Buy Stock
02:58pm, Friday, 23'rd May 2025
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
04:05pm, Thursday, 08'th May 2025
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edg
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
04:05pm, Monday, 05'th May 2025
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fu
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
04:05pm, Monday, 28'th Apr 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
10:46am, Wednesday, 16'th Apr 2025
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Relay Therapeutics: Trying To Find That Right Price
09:28am, Saturday, 12'th Apr 2025
Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, sho
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)
10:36am, Wednesday, 05'th Mar 2025
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
04:05pm, Wednesday, 26'th Feb 2025
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
04:05pm, Monday, 24'th Feb 2025
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
04:05pm, Wednesday, 19'th Feb 2025
CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed
